Recent

% | $
Quotes you view appear here for quick access.

Geron Corporation (GERN) Message Board

  • lws2000 lws2000 May 22, 2014 7:27 AM Flag

    There are No Negatives (Imetelstat); Colorado vs. the FDA; Curious "Hold"

    Colorado has based its new Right-to-Try-Law on the failure of the FDA to recognize the needs of certain patients for drugs that look very promising. The center of attention is blood cancers, which certainly involves Imetelstat. Mayo recommends this drug, and the FDA "hold" is mostly procedural (not scientific). The "hold" is on its way out, because the FDA will not politically take on the State of Colorado over a curious, questionable "hold".

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • How would you suggest that GERN take advantage of the Right-to-Try-Law in Colorado?

      Let's face it, chippy has not been creative and doesn't think out of the box. He seems lost most of the time.

      Of course, IMO.

      • 2 Replies to blackmarango
      • Nothing matters except Mayo's continuing, 100% support. Mayo's reputation for medical skill and honesty makes everything else irrelevant. The FDA hold is a temporary annoyance.

      • Blood Cancer is the reason for the new law. I have not found a specific reference to Imetelstat, but that likely is the drug of interest (brother of state senator that introduced the bill). Colorado will start to give limited approvals, and will not need FDA approval (state's rights). I would hope that Imetelstat will get a needed boost here.

        Previous###. Imetelstat still has its miracle-drug status, and the full support of Mayo Clinic. There seems to be no evidence to contradict the positive results that have come from the continuing Mayo trials, but there is much to be learned. Telomere research and its links to genetic science are a key part of the 21st century medical universe (the next 85 years and beyond). This is just the beginning. The FDA-hold seems to be ready for modification, since there is no apparent reason to keep it in place as it is. Colorado's interest in blood cancer patients (the case behind the new law) will influence the process.###

    • It seems to me that this is a "bet" with a high probability of success. I hesitate to buy more because I do not understand the market control that can pull this stock back to $2 over and over again. I think there will be a break out to the upside, but who knows. The more one believes, the more one can be disappointed.

 
GERN
3.86+0.02(+0.65%)May 29 4:00 PMEDT